← Eichor
Study identifier: NCT04215224 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence

Condition: Glioma  ·  Sponsor: The First Affiliated Hospital of Zhengzhou University

PhaseN/A
Planned participants3500
Who can joinAll sexes, 1 Year to 90 Years
Healthy volunteersNo

About this study

This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

This description comes directly from the study's public registry record.

Talk to the study team

Zhenyu Zhang, Dr.  ·  +86 17839973727  ·  fcczhangzy1@zzu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Neurosurgery, First Affiliated Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04215224